Targeting cyclin-dependent kinases in anti-neoplastic therapy

被引：77
作者：
Bruyere, Celine [1 ]
Meijer, Laurent [1 ]
机构：
[1] ManRos Therapeut, Ctr Perharidy, F-29680 Roscoff, France
来源：
CURRENT OPINION IN CELL BIOLOGY | 2013年 / 25卷 / 06期
关键词：
PROTEIN RECOGNITION PROPERTIES; LYMPHOCYTIC-LEUKEMIA CELLS; BREAST-CANCER; CDK INHIBITORS; CRYSTAL-STRUCTURE; DOWN-REGULATION; CHEMICAL INHIBITORS; N-MYC; COMPLEX; PHOSPHORYLATION;
D O I：
10.1016/j.ceb.2013.08.004
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
Cell cycle progression is controlled by sequential activation of cyclin-dependent kinases (CDKs), which are often deregulated in cancer. Consequently numerous pharmacological inhibitors of CDKs have been developed with the aim of treating cancers. The article briefly reviews CDK inhibitors and their use to treat cancers, with specific focus on the use of biomarkers and drugs combination to improve their therapeutic efficacy.
引用
收藏
页码：772 / 779
页数：8
相关论文
共 84 条
  • [1] ATP-noncompetitive CDK inhibitors for cancer therapy: an overview
    Abate, Agnese Anna
    Pentimalli, Francesca
    Esposito, Luca
    Giordano, Antonio
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (07) : 895 - 906
  • [2] Cdk2 is Required for Breast Cancer Mediated by the Low-Molecular-Weight Isoform of Cyclin E
    Akli, Said
    Van Pelt, Carolyn S.
    Bui, Tuyen
    Meijer, Laurent
    Keyomarsi, Khandan
    [J]. CANCER RESEARCH, 2011, 71 (09) : 3377 - 3386
  • [3] Potent Antimyeloma Activity of a Novel ERK5/CDK Inhibitor
    Alvarez-Fernandez, Stela
    Jesus Ortiz-Ruiz, Maria
    Parrott, Tracy
    Zaknoen, Sara
    Ocio, Enrique M.
    San Miguel, Jesus
    Burrows, Francis J.
    Esparis-Ogando, Azucena
    Pandiella, Atanasio
    [J]. CLINICAL CANCER RESEARCH, 2013, 19 (10) : 2677 - 2687
  • [4] Functional characterisation of cell cycle-related kinase (CCRK) in colorectal cancer carcinogenesis
    An, Xiaomeng
    Ng, Samuel S.
    Xie, Dan
    Zeng, Yi-Xin
    Sze, Johnny
    Wang, Jide
    Chen, Yang Chao
    Chow, Billy K. C.
    Lu, Gang
    Poon, Wai Sang
    Kung, Hsiang-fu
    Wong, Benjamin C. Y.
    Lin, Marie Chia-mi
    [J]. EUROPEAN JOURNAL OF CANCER, 2010, 46 (09) : 1752 - 1761
  • [5] Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity
    Anastassiadis, Theonie
    Deacon, Sean W.
    Devarajan, Karthik
    Ma, Haiching
    Peterson, Jeffrey R.
    [J]. NATURE BIOTECHNOLOGY, 2011, 29 (11) : 1039 - U117
  • [6] Roscovitine targets, protein kinases and pyridoxal kinase
    Bach, S
    Knockaert, M
    Reinhardt, J
    Lozach, O
    Schmitt, S
    Baratte, B
    Koken, M
    Coburn, SP
    Tang, L
    Jiang, T
    Liang, DC
    Galons, H
    Dierick, JF
    Pinna, LA
    Meggio, F
    Totzke, F
    Schächtele, C
    Lerman, AS
    Carnero, A
    Wan, YQ
    Gray, N
    Meijer, L
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (35) : 31208 - 31219
  • [7] Baker Stacey J, 2012, Genes Cancer, V3, P658, DOI 10.1177/1947601913478972
  • [8] The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation
    Baumli, Sonja
    Lolli, Graziano
    Lowe, Edward D.
    Troiani, Sonia
    Rusconi, Luisa
    Bullock, Alex N.
    Debreczeni, Judit E.
    Knapp, Stefan
    Johnson, Louise N.
    [J]. EMBO JOURNAL, 2008, 27 (13) : 1907 - 1918
  • [9] Characterization of Cyclin E Expression in Multiple Myeloma and Its Functional Role in Seliciclib-Induced Apoptotic Cell Death
    Ben-Yehoshua, Liat Josefsberg
    Beider, Katia
    Shimoni, Avichai
    Ostrovsky, Olga
    Samookh, Michal
    Peled, Amnon
    Nagler, Arnon
    [J]. PLOS ONE, 2012, 7 (04): : e33856
  • [10] CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases
    Bettayeb, K.
    Oumata, N.
    Echalier, A.
    Ferandin, Y.
    Endicott, J. A.
    Galons, H.
    Meijer, L.
    [J]. ONCOGENE, 2008, 27 (44) : 5797 - 5807
123456789